Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies
Published: 4 November 2022| Version 1 | DOI: 10.17632/9n7tfyss53.1
Contributor:
Lee HohaiaDescription
Supplemental Appendix for an article "Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies" published in the Journal of the American Academy of Dermatology
Files
Categories
Atopic Dermatitis